IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1076-1100 out of 1364.

<< < 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 > >>

Public Release: 17-Feb-2015
Nature Chemistry
From the scent of geranium to cough medicine
Terpenes and their derivatives exert important biological and pharmaceutical functions. Starting out from a few basic building blocks nature elegantly builds up complex structures. Chemically particularly challenging are bridged ring systems such as eucalyptol. Chemists at the Technische Universität München have now developed a catalyst that initiates the formation of such compounds. A special feature of the catalyst: it self-assembles from smaller units.
BAdW, VCI, TUM Junior Fellow Fund, Dr.-Ing. Leonhard-Lorenz-Stiftung

Contact: Dr. Andreas Battenberg
battenberg@zv.tum.de
49-892-891-0510
Technical University of Munich (TUM)

Public Release: 17-Feb-2015
Clinical Cancer Research
New study reveals how to improve chemotherapy use in prostate cancer
Next generation chemotherapy for prostate cancer has unique properties that could make it more effective earlier in treatment if confirmed in clinical trials.

Contact: Edyta Zielinska
edyta.zielinska@jefferson.edu
215-955-5291
Thomas Jefferson University

Public Release: 17-Feb-2015
Nature Reviews Clinical Oncology
Learning from extinction: New insights on controlling cancer
Carlo Maley, Ph.D., a researcher at Arizona State University's Biodesign Institute and School of Life Sciences brings a paleontological view of species extinction to bear on the challenges involved in driving populations of cancer cells to annihilation -- or at least improving patient prognosis through disease-limiting efforts.

Contact: Joseph Caspermeyer
Joseph.Caspermeyer@asu.edu
Arizona State University

Public Release: 17-Feb-2015
Journal of Clinical Investigation
Bile duct cancer study may pave way for new treatments
Patients with bile duct cancer could be helped by a new class of experimental drug, a laboratory study led by the University of Edinburgh has shown.

Contact: Jen Middleton
jen.middleton@ed.ac.uk
44-131-650-6514
University of Edinburgh

Public Release: 17-Feb-2015
Lancet
Better informed women less likely to want a breast mammogram -- world first Lancet study
Women who understand the risk of over-detection and over-diagnosis associated with mammography screening have lower intentions to have a breast screening test, according to a new Lancet study.

Contact: Kirsten McCaffery
kirstenm@health.usyd.edu.au
61-403-941-875
University of Sydney

Public Release: 16-Feb-2015
Nature Medicine
New therapeutic strategy discovered for ovarian cancer
Ovarian cancer is the deadliest of all cancers affecting the female reproductive system with very few effective treatments available. Prognosis is even worse among patients with certain subtypes of the disease. Now, researchers at The Wistar Institute have identified a new therapeutic target in a particularly aggressive form of ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease.
National Institutes of Health, US Department of Defense, American Cancer Society, Ovarian Cancer Research Fund

Contact: Ben Leach
bleach@wistar.org
215-495-6800
The Wistar Institute

Public Release: 16-Feb-2015
Proceedings of the National Academy of Sciences
Gene mutation drives cartilage tumor formation
Duke Medicine researchers have shown how gene mutations may cause common forms of cartilage tumors. In a study published in the Feb. 16, 2015, issue of the Proceedings of the National Academy of Sciences, Duke researchers and their colleagues revealed that mutations in the isocitrate dehydrogenase gene contribute to the formation of benign tumors in cartilage that can be a precursor to malignancies.
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases

Contact: Sarah Avery
sarah.avery@duke.edu
919-660-1306
Duke University Medical Center

Public Release: 16-Feb-2015
Mayo Clinic: Molecule that provides cellular energy found key to aggressive thyroid cancer
Cancer researchers at Mayo Clinic's campus in Jacksonville, Florida, have identified a molecule they say is important to survival of anaplastic thyroid carcinoma -- a lethal tumor with no effective therapies. The molecule also seems to play a role in a wide range of cancers.
NIH/National Cancer Institute, Florida Department of Health Bankhead-Coley Cancer Research Program, Mr. and Mrs. Ompal Chauhan Research Fund, Scheidel Foundation, Fraternal Order of Eagles Florida State Auxiliary

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-0746
Mayo Clinic

Public Release: 16-Feb-2015
Oncology Nursing Forum
Cancer experience presents time for lifestyle changes in both survivors and family members
After studying cancer survivors and their family caregivers, researchers at Case Western Reserve University conclude that the period between the final cancer treatment and first post-treatment checkup may be an ideal time for the entire household to jumpstart a healthy lifestyle.
National Institutes of Health and National Cancer Institute's Prevention Research Educational Postdoctoral Training Program

Contact: Susan Griffith
susan.griffith@case.edu
216-368-1004
Case Western Reserve University

Public Release: 16-Feb-2015
Nature Cell Biology
Lack of RNA 'editing' leads to melanoma growth and metastasis
The importance of RNA editing in melanoma has been demonstrated by scientists at The University of Texas MD Anderson Cancer Center. The study revealed that a lack of RNA editing, a process by which information inside RNA molecules is transformed, leads to tumor growth and progression through manipulation of proteins.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Public Release: 15-Feb-2015
Cancer Research
Human neural stem cells restore cognitive functions impaired by chemotherapy
Human neural stem cell treatments are showing promise for reversing learning and memory deficits after chemotherapy, according to UC Irvine radiation oncology researchers.
National Institutes of Health, UC Irvine's Institute for Clinical & Translational Science

Contact: Tom Vasich
tmvasich@uci.edu
949-285-6455
University of California - Irvine

Public Release: 13-Feb-2015
Journal of Operating Department Practitioners
Diathermy smoke extraction should be compulsory in operations
The electrical devices that are used to cauterize tissue during surgical operations cause plumes of smoke to arise as intense heat is applied to flesh. Research has shown that these fumes -- known as diathermy smoke -- contain compounds that are potentially harmful to the health of the personnel participating in the operation. Now an article by a University of Huddersfield lecturer aims to bolster the case for the use of devices that extract the fumes, reducing risk levels.

Contact: Nicola Werritt
n.c.werritt@hud.ac.uk
01-484-473-315
University of Huddersfield

Public Release: 13-Feb-2015
Journal of Clinical Oncology
Survivors of childhood cancer at risk for developing hormone deficiencies as adults
Decades after undergoing cranial irradiation for childhood cancer, St. Jude Children's Research Hospital investigators found that adult survivors of pediatric cancer remain at risk for pituitary hormone deficiencies that may diminish their health and quality of life. The findings appear in the February 10 edition of the Journal of Clinical Oncology.
NIH/National Cancer Institute, American Lebanese Syrian Associated Charities

Contact: Carrie Strehlau
carrie.strehlau@stjude.org
901-595-2295
St. Jude Children's Research Hospital

Public Release: 13-Feb-2015
Proceedings of the National Academy of Sciences
NUS pioneers novel strategy to prevent progression of inflammation-associated cancers
A team of researchers led by associate professor Caroline Lee from the Yong Loo Lin School of Medicine at the National University of Singapore, in collaboration with associate professor Song Jianxing of the Department of Biological Sciences at the National University of Singapore Faculty of Science, has developed a novel strategy in the fight against cancer.

Contact: Carolyn Fong
carolyn@nus.edu.sg
65-651-65399
National University of Singapore

Public Release: 13-Feb-2015
Analytical Chemistry
UT Arlington bio-analytical chemist receives NIH, UT System funding for protein research
UT Arlington bio-analytical chemist Saiful Chowdhury has received funding from the NIH and UT System to advance protein research. His work, involving mass spectrometry, is also discussed in the journal Analytical Chemistry.
National Institutes of Health, The University of Texas System

Contact: Bridget Lewis
blewis@uta.edu
817-272-3317
University of Texas at Arlington

Public Release: 13-Feb-2015
BioData Mining
Google-style ranking used to describe gene connectivity
Using the technique known as 'Gene Rank,' Dartmouth investigator Eugene Demidenko, Ph.D., captured and described a new characterization of gene connectivity in 'Microarray Enriched Gene Rank,' published in BioData Mining. The effective computer algorithm can be used to compare tissues across or within organisms at great speed with a simple laptop computer.
National Institutes of Health

Contact: Kirk Cassels
Kirk.A.Cassels@Hitchcock.org
603-653-6177
The Geisel School of Medicine at Dartmouth

Public Release: 13-Feb-2015
Biotechnology and Bioengineering
Structure-based design used as tool for engineering deimmunized biotherapeutics
In the first experimental use of algorithms that employ structure-based molecular modeling to optimize deimmunized drug candidates, Dartmouth researchers complement their prior sequence-based deimmunizing algorithms and expand the tool kit of protein engineering technologies to use in next generation drug development.
National Institutes of Health, Luce Foundation, National Science Foundation

Contact: Kirk Cassels
kirk.A.Cassels@Hitchcock.org
603-653-6177
The Geisel School of Medicine at Dartmouth

Public Release: 12-Feb-2015
JAMA Oncology
Physician-controlled decisions in cancer care linked to lower quality rating
Patients who described physician-controlled decisions about their cancer care versus shared decision-making were less likely to report receiving excellent quality of care, according to a study published online by JAMA Oncology.

Contact: David Cameron
david_cameron@hms.harvard.edu
617-432-0441
The JAMA Network Journals

Public Release: 12-Feb-2015
JAMA Oncology
Clinically inappropriate patient demands of oncologists happen infrequently
While many physicians will cite 'demanding patients' as the reason for high medical costs due to unnecessary tests or treatments, a new study conducted at outpatient oncology centers found that only 1 percent of 5,050 patient-clinician encounters resulted in a clinically inappropriate request, of which very few were complied with by physicians, according to a study published online by JAMA Oncology.

Contact: Anna Duerr
anna.duerr@uphs.upenn.edu
215-349-8369
The JAMA Network Journals

Public Release: 12-Feb-2015
JAMA
Moffitt physicians promote screening strategies for those at high-risk for melanoma
Melanoma, the most deadly type of skin cancer, was to blame for approximately 9,700 deaths in 2014. And with the number of melanoma cases increasing each year, it is believed that the disease could become one of the most common types of cancer in the United States by 2030. Promoting and developing national screening strategies may help to reduce deaths due to melanoma.

Contact: Kim Polacek
Kim.Polacek@Moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 12-Feb-2015
JAMA Oncology
Genomic profiling for cancer of unknown primary site
Genomic profiling of cancer of an unknown primary site found at least one clinically relevant genomic alteration in most of the samples tested, an indication of potential to influence and personalize therapy for this type of cancer, which responds poorly to nontargeted chemotherapy treatments, according to a study published online by JAMA Oncology.

Contact: Dan Budwick
dan@purecommunicationsinc.com
973-271-6085
The JAMA Network Journals

Public Release: 12-Feb-2015
Journal of the National Cancer Institute
Two cell-signaling molecules found to suppress the spread of melanoma
In what is believed to be the largest epigenetic analysis to date of cell-signaling molecules in early-stage melanoma, researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center have identified two tiny bits of non-coding genetic material in primary tumors that appear critical to stalling the cancer's spread -- and essentially setting the biological fate of the disease.

Contact: David March
david.march@nyumc.org
212-404-3528
NYU Langone Medical Center / New York University School of Medicine

Public Release: 12-Feb-2015
Nucleic Acids Research
A*STAR develops systems to identify treatment targets for cancer and rare diseases
In recent months, several national initiatives for personalized medicine have been announced, including the recently launched precision medicine initiative in the US, driven by rapid advances in genomic technologies and with the promise of cheaper and better healthcare. Significant challenges remain, however, in the management and analysis of genetic information and their integration with patient data.
A*STAR

Contact: Winnie Lim
limcp2@gis.a-star.edu.sg
65-680-88013
Biomedical Sciences Institutes (BMSI)

Public Release: 12-Feb-2015
Journal of Molecular Diagnostics
JMD publishes article on laboratory perspective of incidental findings reporting
This paper offers new and important perspectives from the laboratory highlighting the need for increased understanding and transparency of complex genomic testing. It also outlines important recommendations, including the need for laboratories to establish clear and patient-friendly policies for delivering ancillary information generated from genome-wide genetic tests.

Contact: Maurissa Messier
maurissa@bioscribe.com
760-659-6700
Association for Molecular Pathology

Public Release: 12-Feb-2015
The Lancet Oncology
Study in Lancet Oncology sheds light on YONDELIS prolonged therapy in soft-tissue sarcoma
PharmaMar announced today that The Lancet Oncology published online the results from a final analysis of a randomized phase 2 trial study which found that treatment continuation with trabectedin in advanced STS patients who have not progressed after six cycles of treatment increases progression-free survival. The data indicate that continued treatment may be recommended for these patients until treatment intolerance or disease given the manageable safety profile and lack of cumulative toxicity of trabectedin.
The French National Cancer Institute, PharmaMar

Contact: Carolina Pola
cpola@pharmamar.com
34-608-933-677
Pharmamar

Showing releases 1076-1100 out of 1364.

<< < 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 > >>

  Search News Releases

     

 

EurekAlert!